Answers are grounded in this paper and cite their sources.
BACKGROUND: Serologic testing for herpes simplex virus type-2 (HSV-2) is being implemented in sexually transmitted disease (STD) clinics. GOAL: To determine the performance characteristics of two HSV-2 type-specific serologic assays in a public health laboratory. STUDY DESIGN: Sera stored from a cross-sectional study were tested with the Meridian Diagnostics and Focus Technologies HSV-2 ELISA tests and a type-specific strip immunoblot assay (Chiron Corp.) was used as the reference standard. RESULTS: Prevalence of HSV-2 infection in this sample was 44%. Compared to the reference standard, the sensitivity of the Meridian Diagnostics HSV-2 test was 95.5% (95% CI 83.3, 99.2) and specificity was 98.2% (95% CI 89.0, 99.9). The Focus Technologies test yielded 97.7% (95% CI 86.5, 99.9) sensitivity and 94.5% (95% CI 83.9, 98.6) specificity. CONCLUSIONS: The performance of these HSV-2 type-specific serologic assays was adequate to support their use in high prevalence populations, such as STD clinic patients.
No takes yet. Share an insight, caveat, or question.
Turner et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: